PharmaShots | Incisive News in 3 Shots

Subscribe Now

Platinum-Sensitive

AstraZeneca and MSD Report Results of Cediranib + Lynparza in P-III GY004 Study for Patients with Platinum-Sensitive Relapsed Ovarian Cancer

AstraZeneca and MSD Report Results of Cediranib + Lynparza in P-III GY004 Study for Patients with Platinum-Sensitive Relapsed Ovar...

March 13, 2020

AstraZeneca and Merck Report Results of Lynparza (olaparib) in P-III SOLO3 Study for Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer #ASCO2019

AstraZeneca and Merck Report Results of Lynparza (olaparib) in P-III SOLO3 Study for Platinum-Sensitive Relapsed Germline BRCA-mut...

June 4, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us